cipla ltd
Pfizer tells Centre its vaccine suitable for 12 years and above
The drugmaker is likely to supply 50 million COVID-19 vaccines to India in 2021, albeit with a few conditions
Cipla to price remdesivir version for COVID-19 under Rs 5,000
Gilead said on Monday it is targeting remdesivir supply for more than 2 million COVID-19 patients by the end of the year.
1 of 1